Detalhe da pesquisa
1.
Semirational bioengineering of AAV vectors with increased potency and specificity for systemic gene therapy of muscle disorders.
Sci Adv
; 8(38): eabn4704, 2022 09 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-36129972
2.
Preclinical Development of an AAV8-hUGT1A1 Vector for the Treatment of Crigler-Najjar Syndrome.
Mol Ther Methods Clin Dev
; 12: 157-174, 2019 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30705921
3.
The EB66® cell line as a valuable cell substrate for MVA-based vaccines production.
Vaccine
; 34(48): 5878-5885, 2016 11 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-27997338